Víctor Hugo Vázquez-Valadez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Víctor Hugo Vázquez-Valadez has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Enrique Angeles
Laboratorio de Química Teórica y Medicinal, Departamento de Ciencias Químicas, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Cuautitlán Izcalli 54750, Mexico
6 shared publications - Aldo Yoshio Alarcón-López
Departamento de Ciencias Químicas FES Cuautitlán Universidad Nacional Autónoma de México (UNAM) Av. 1 de Mayo SN Cuautitlán Izcalli Mexico City 54740 Mexico
5 shared publications - Luis Alfonso Cárdenas Granados
Laboratorio de Química Medicinal y Teórica FES Cuautitlán Universidad Nacional Autónoma de México (UNAM) Campo 1 Av. 1 de Mayo SN Cuautitlán Izcalli Mexico City 54740 Mexico
5 shared publications - Manuel Alejandro Hernández-Serda
Departamento de Ciencias Químicas FES Cuautitlán Universidad Nacional Autónoma de México (UNAM) Av. 1 de Mayo SN Cuautitlán Izcalli Mexico City 54740 Mexico
5 shared publications - Ana María Velázquez-Sánchez
Departamento de Ciencias Químicas FES Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Av. 1 de Mayo SN Cuautitlán Izcalli, Mexico City 54750, Mexico
3 shared publications - Pablo A. Martínez-Soriano
Departamento de Ciencias Químicas FES Cuautitlán Universidad Nacional Autónoma de México (UNAM) Av. 1 de Mayo SN Cuautitlán Izcalli Mexico City 54740 Mexico
3 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by Brazilian Journals in Brazilian Journal of Animal and Environmental Research
- Vol. 8 (4) , e84722
The inhibitory activity of propoxur on acetylcholinesterase varies among domestic animal species
The aim of this study was to compare in silico (molecular docking) affinity of acetylcholinesterase (AChE) from different objective and non-objective animal species (cattle ticks, honeybees, chickens, rats, humans, rabbits, pigs, sheep, goats, and cattle) to propoxur, and in vitro the inhibition kinetics of AChE activity produced by this compound. Molecular docking showed that the number of amino acids in AChE varied among the species. The catalytic triad (His, Glu, and Ser) was conserved, although its position within the protein varied among species. The lowest similarity in protein identity was between arthropods compared to mammals and chickens. In silico predictions showed that propoxur has a higher affinity energy but lower binding efficiency to AChE than acetylcholine. In vitro kinetic constants (Km and Vmax) showed clear differences in enzyme affinity and activity between species. Furthermore, differences in the inhibition kinetic constants of propoxur on AChE were observed between species. A higher inhibitory power (ki), higher carbamylation rate (k2), lower dissociation rate (kd), and lower IC50 values were observed in porcine AChE inhibited by propoxur compared with those of AChE from the other species, suggesting that pigs have higher susceptibility to propoxur. In contrast, a lower carbamylation rate and higher IC50 value were observed in cattle, suggesting a greater resistance in cattle and differences in vivo susceptibility between non-objective species to propoxur. In silico and in vitro results reveal a differentiated effect of propoxur on AChE activity in different species and its neurotoxic potential.
- 1 October 2025
- Published by Brazilian Journals in Brazilian Journal of Animal and Environmental Research
- Vol. 8 (4) , e84722
Open AccessThe inhibitory activity of propoxur on acetylcholinesterase varies among domestic animal species
The aim of this study was to compare in silico (molecular docking) affinity of acetylcholinesterase (AChE) from different objective and non-objective animal species (cattle ticks, honeybees, chickens, rats, humans, rabbits, pigs, sheep, goats, and cattle) to propoxur, and in vitro the inhibition kinetics of AChE activity produced by this compound. Molecular docking showed that the number of amino acids in AChE varied among the species. The catalytic triad (His, Glu, and Ser) was conserved, although its position within the protein varied among species. The lowest similarity in protein identity was between arthropods compared to mammals and chickens. In silico predictions showed that propoxur has a higher affinity energy but lower binding efficiency to AChE than acetylcholine. In vitro kinetic constants (Km and Vmax) showed clear differences in enzyme affinity and activity between species. Furthermore, differences in the inhibition kinetic constants of propoxur on AChE were observed between species. A higher inhibitory power (ki), higher carbamylation rate (k2), lower dissociation rate (kd), and lower IC50 values were observed in porcine AChE inhibited by propoxur compared with those of AChE from the other species, suggesting that pigs have higher susceptibility to propoxur. In contrast, a lower carbamylation rate and higher IC50 value were observed in cattle, suggesting a greater resistance in cattle and differences in vivo susceptibility between non-objective species to propoxur. In silico and in vitro results reveal a differentiated effect of propoxur on AChE activity in different species and its neurotoxic potential.
- Open Access
- 16 July 2025
- Published by Wiley in ChemistryOpen
- Vol. 14 (11) , e2500107
“Molecular Docking and Dynamic Studies of Amide Derivatives from Cinnamic Acid with Potential Anti‐Dengue Virus Activity”
Dengue, classified as a neglected tropical disease and transmitted by Aedes mosquitoes, remains a significant global health challenge, often evolving into severe clinical manifestations such as hemorrhagic fever. Despite its widespread impact, no antiviral therapy has been approved to date, highlighting the urgent need for effective and accessible treatment options. In the present work, computational analysis is performed on an in‐house library of easily synthesized caffeic acid phenethyl ester analogs, which exhibit potential activity against the viral envelope (E) protein, a critical mediator of dengue virus entry and membrane fusion. Among them, LQM778 demonstrated consistent stability within the protein–ligand complex during molecular dynamics simulations. This finding provides a foundation for in vitro studies and future structural optimizations that could transform the landscape of antiviral development against dengue.
- 16 July 2025
- Published by Wiley in ChemistryOpen
- Vol. 14 (11) , e2500107
Open Access“Molecular Docking and Dynamic Studies of Amide Derivatives from Cinnamic Acid with Potential Anti‐Dengue Virus Activity”
Dengue, classified as a neglected tropical disease and transmitted by Aedes mosquitoes, remains a significant global health challenge, often evolving into severe clinical manifestations such as hemorrhagic fever. Despite its widespread impact, no antiviral therapy has been approved to date, highlighting the urgent need for effective and accessible treatment options. In the present work, computational analysis is performed on an in‐house library of easily synthesized caffeic acid phenethyl ester analogs, which exhibit potential activity against the viral envelope (E) protein, a critical mediator of dengue virus entry and membrane fusion. Among them, LQM778 demonstrated consistent stability within the protein–ligand complex during molecular dynamics simulations. This finding provides a foundation for in vitro studies and future structural optimizations that could transform the landscape of antiviral development against dengue.
- Open Access
In Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro)
The ongoing Coronavirus Disease 19 (COVID-19) pandemic has had a profound impact on the global healthcare system. As the SARS-CoV-2 virus, responsible for this pandemic, continues to spread and develop mutations in its genetic material, new variants of interest (VOIs) and variants of concern (VOCs) are emerging. These outbreaks lead to a decrease in the efficacy of existing treatments such as vaccines or drugs, highlighting the urgency of new therapies for COVID-19. Therefore, in this study, we aimed to identify potential SARS-CoV-2 antivirals using a virtual screening protocol and molecular dynamics simulations. These techniques allowed us to predict the binding affinity of a database of compounds with the virus Mpro protein. This in silico approach enabled us to identify twenty-two chemical structures from a public database (QSAR Toolbox Ver 4.5 ) and ten promising molecules from our in-house database. The latter molecules possess advantageous qualities, such as two-step synthesis, cost-effectiveness, and long-lasting physical and chemical stability. Consequently, these molecules can be considered as promising alternatives to combat emerging SARS-CoV-2 variants.
Open AccessIn Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro)
The ongoing Coronavirus Disease 19 (COVID-19) pandemic has had a profound impact on the global healthcare system. As the SARS-CoV-2 virus, responsible for this pandemic, continues to spread and develop mutations in its genetic material, new variants of interest (VOIs) and variants of concern (VOCs) are emerging. These outbreaks lead to a decrease in the efficacy of existing treatments such as vaccines or drugs, highlighting the urgency of new therapies for COVID-19. Therefore, in this study, we aimed to identify potential SARS-CoV-2 antivirals using a virtual screening protocol and molecular dynamics simulations. These techniques allowed us to predict the binding affinity of a database of compounds with the virus Mpro protein. This in silico approach enabled us to identify twenty-two chemical structures from a public database (QSAR Toolbox Ver 4.5 ) and ten promising molecules from our in-house database. The latter molecules possess advantageous qualities, such as two-step synthesis, cost-effectiveness, and long-lasting physical and chemical stability. Consequently, these molecules can be considered as promising alternatives to combat emerging SARS-CoV-2 variants.
- Open Access
- 13 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 8812
Hypoxic Cardioprotection by New Antihypertensive Compounds in High Salt-Diet Hypertensive Rats: Glucose Transport Participation and Its Possible Pathway
Hypertension (HP) is a health condition that overloads the heart and increases the risk of heart attack and stroke. In an infarction, the lack of oxygen causes an exclusive use of glycolysis, which becomes a crucial source of ATP for the heart with a higher glucose uptake mediated by glucose transporters (GLUTs). Due to the unpleasant effects of antihypertensives, new drugs need to be researched to treat this disease. This study aimed to evaluate the cardioprotective effect of three novel antihypertensive compounds (LQMs, “Laboratorio de Química Medicinal”) synthesized from Changrolin under hypoxic conditions with the participation of two primary cardiac GLUT1 and GLUT4 using a high-salt diet HP model. The model used a diet with 10% salt to increase arterial blood pressure in Wistar rats. In isolated cardiomyocytes from these rats, glucose uptake was measured during hypoxia, evaluating the participation of GLUTs with or without the animals’ previous treatment with LQM312, 319, and 345 compounds. In silico calculations were performed to understand the affinity of the compounds for the trafficking of GLUTs. Results: Control cells do shift to glucose uptake exclusively in hypoxia (from 1.84 ± 0.09 µg/g/h to 2.67 ± 0.1 µg/g/h). Meanwhile, HP does not change its glucose uptake (from 2.38 ± 0.24 µg/g/h to 2.33 ± 0.26 µg/g/h), which is associated with cardiomyocyte damage. The new compounds lowered the systolic blood pressure (from 149 to 120 mmHg), but only LQM312 and LQM319 improved the metabolic state of hypoxic cardiomyocytes mediated by GLUT1 and GLUT4. In silico studies suggested that Captopril and LQM312 may mimic the interaction with the AMPK γ-subunit. Therefore, these compounds could activate AMPK, promoting the GLUT4 trafficking signaling pathway. These compounds are proposed to be cardioprotective during hypoxia under HP.
- 13 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 8812
Open AccessHypoxic Cardioprotection by New Antihypertensive Compounds in High Salt-Diet Hypertensive Rats: Glucose Transport Participation and Its Possible Pathway
Hypertension (HP) is a health condition that overloads the heart and increases the risk of heart attack and stroke. In an infarction, the lack of oxygen causes an exclusive use of glycolysis, which becomes a crucial source of ATP for the heart with a higher glucose uptake mediated by glucose transporters (GLUTs). Due to the unpleasant effects of antihypertensives, new drugs need to be researched to treat this disease. This study aimed to evaluate the cardioprotective effect of three novel antihypertensive compounds (LQMs, “Laboratorio de Química Medicinal”) synthesized from Changrolin under hypoxic conditions with the participation of two primary cardiac GLUT1 and GLUT4 using a high-salt diet HP model. The model used a diet with 10% salt to increase arterial blood pressure in Wistar rats. In isolated cardiomyocytes from these rats, glucose uptake was measured during hypoxia, evaluating the participation of GLUTs with or without the animals’ previous treatment with LQM312, 319, and 345 compounds. In silico calculations were performed to understand the affinity of the compounds for the trafficking of GLUTs. Results: Control cells do shift to glucose uptake exclusively in hypoxia (from 1.84 ± 0.09 µg/g/h to 2.67 ± 0.1 µg/g/h). Meanwhile, HP does not change its glucose uptake (from 2.38 ± 0.24 µg/g/h to 2.33 ± 0.26 µg/g/h), which is associated with cardiomyocyte damage. The new compounds lowered the systolic blood pressure (from 149 to 120 mmHg), but only LQM312 and LQM319 improved the metabolic state of hypoxic cardiomyocytes mediated by GLUT1 and GLUT4. In silico studies suggested that Captopril and LQM312 may mimic the interaction with the AMPK γ-subunit. Therefore, these compounds could activate AMPK, promoting the GLUT4 trafficking signaling pathway. These compounds are proposed to be cardioprotective during hypoxia under HP.
- Open Access
- 29 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (1) , 475
In Vivo and In Silico Studies of the Hepatoprotective Activity of Tert-Butylhydroquinone
Tert-butylhydroquinone (TBHQ) is a synthetic food antioxidant with biological activities, but little is known about its pharmacological benefits in liver disease. Therefore, this work aimed to evaluate TBHQ during acute liver damage induced by CCl4 (24 h) or BDL (48 h) in Wistar rats. It was found that pretreatment with TBHQ prevents 50% of mortality induced by a lethal dose of CCl4 (4 g/kg, i.p.), and 80% of BDL+TBHQ rats survived, while only 50% of the BDL group survived. Serum markers of liver damage and macroscopic and microscopic (H&E staining) observations suggest that TBHQ protects from both hepatocellular necrosis caused by the sublethal dose of CCl4 (1.6 g/kg, i.p.), as well as necrosis/ductal proliferation caused by BDL. Additionally, online databases identified 49 potential protein targets for TBHQ. Finally, a biological target candidate (Keap1) was evaluated in a proof-of-concept in silico molecular docking assay, resulting in an interaction energy of −5.5491 kcal/mol, which was higher than RA839 and lower than monoethyl fumarate (compounds known to bind to Keap1). These findings suggest that TBHQ increases the survival of animals subjected to CCl4 intoxication or BDL, presumably by reducing hepatocellular damage, probably due to the interaction of TBHQ with Keap1.
- 29 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (1) , 475
Open AccessIn Vivo and In Silico Studies of the Hepatoprotective Activity of Tert-Butylhydroquinone
Tert-butylhydroquinone (TBHQ) is a synthetic food antioxidant with biological activities, but little is known about its pharmacological benefits in liver disease. Therefore, this work aimed to evaluate TBHQ during acute liver damage induced by CCl4 (24 h) or BDL (48 h) in Wistar rats. It was found that pretreatment with TBHQ prevents 50% of mortality induced by a lethal dose of CCl4 (4 g/kg, i.p.), and 80% of BDL+TBHQ rats survived, while only 50% of the BDL group survived. Serum markers of liver damage and macroscopic and microscopic (H&E staining) observations suggest that TBHQ protects from both hepatocellular necrosis caused by the sublethal dose of CCl4 (1.6 g/kg, i.p.), as well as necrosis/ductal proliferation caused by BDL. Additionally, online databases identified 49 potential protein targets for TBHQ. Finally, a biological target candidate (Keap1) was evaluated in a proof-of-concept in silico molecular docking assay, resulting in an interaction energy of −5.5491 kcal/mol, which was higher than RA839 and lower than monoethyl fumarate (compounds known to bind to Keap1). These findings suggest that TBHQ increases the survival of animals subjected to CCl4 intoxication or BDL, presumably by reducing hepatocellular damage, probably due to the interaction of TBHQ with Keap1.
- Open Access
Evaluation of Inhibitory Activity In Silico of In-House Thiomorpholine Compounds between the ACE2 Receptor and S1 Subunit of SARS-CoV-2 Spike
At the end of 2019, the world was struck by the COVID-19 pandemic, which resulted in dire repercussions of unimaginable proportions. From the beginning, the international scientific community employed several strategies to tackle the spread of this disease. Most notably, these consisted of the development of a COVID-19 vaccine and the discovery of antiviral agents through the repositioning of already known drugs with methods such as de novo design. Previously, methylthiomorphic compounds, designed by our group as antihypertensive agents, have been shown to display an affinity with the ACE2 (angiotensin converting enzyme) receptor, a key mechanism required for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) entry into target cells. Therefore, the objective of this work consists of evaluating, in silico, the inhibitory activity of these compounds between the ACE2 receptor and the S1 subunit of the SARS-CoV-2 spike protein. Supported by the advances of different research groups on the structure of the coronavirus spike and the interaction of the latter with its receptor, ACE2, we carried out a computational study that examined the effect of in-house designed compounds on the inhibition of said interaction. Our results indicate that the polyphenol LQM322 is one of the candidates that should be considered as a possible anti-COVID-19 agent.
Open AccessEvaluation of Inhibitory Activity In Silico of In-House Thiomorpholine Compounds between the ACE2 Receptor and S1 Subunit of SARS-CoV-2 Spike
At the end of 2019, the world was struck by the COVID-19 pandemic, which resulted in dire repercussions of unimaginable proportions. From the beginning, the international scientific community employed several strategies to tackle the spread of this disease. Most notably, these consisted of the development of a COVID-19 vaccine and the discovery of antiviral agents through the repositioning of already known drugs with methods such as de novo design. Previously, methylthiomorphic compounds, designed by our group as antihypertensive agents, have been shown to display an affinity with the ACE2 (angiotensin converting enzyme) receptor, a key mechanism required for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) entry into target cells. Therefore, the objective of this work consists of evaluating, in silico, the inhibitory activity of these compounds between the ACE2 receptor and the S1 subunit of the SARS-CoV-2 spike protein. Supported by the advances of different research groups on the structure of the coronavirus spike and the interaction of the latter with its receptor, ACE2, we carried out a computational study that examined the effect of in-house designed compounds on the inhibition of said interaction. Our results indicate that the polyphenol LQM322 is one of the candidates that should be considered as a possible anti-COVID-19 agent.
- 1 September 2016
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 807, 8-14
Genotoxicity and cytotoxicity assessment of new ethyl-carbamates with ixodicidal activity
- 1 September 2016
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 807, 8-14
Genotoxicity and cytotoxicity assessment of new ethyl-carbamates with ixodicidal activity